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Manuscript 
 
The current issue of the journal presents an excellent overview of meta-epidemiological studies 
on trial characteristics that have been associated with treatment effect estimates conducted from 
Dechartres et al. [1]. The authors searched several literature sources for meta-epidemiological 
studies and followed a strict systematic review procedure for the selection, extraction, and 
assessment of eligible studies. 
First of all, this overview was a priori registered in the PROSPERO international 
prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO/). It is 
interesting to see the evolution of PROSPERO from an initial register for systematic reviews of 
clinical intervention trials, to a register that encompasses also meta-epidemiological studies 
(overviews) of systematic reviews of clinical studies, and now overviews of meta-epidemiological 
studies. This reflects the simultaneous evolution of complicated meta-research methods, while 
still maintaining their direct clinical relevance, as the latter is a prerequisite for a methodological 
overview to be registered in PROSPERO. 
This study provides an invaluable collection of empirical evidence on a broad variety of 
trial characteristics including typical domains of randomized trials (like sequence generation, 
allocation concealment, blinding of participants, personnel or outcome assessors, incomplete 
outcome, etc) that are incorporated in the Cochrane risk of bias tool [2] or a wide array of 
characteristics like trial design, trial sample size, trial / patient demographics, and funding. The 
produced forest plots provide a concise summary of accumulated empirical evidence of meta-
bias over the years, while descriptive information about the demographics and the methods used 
in the meta-epidemiological studies are given in detail in the provided tables. 
The first impression the reader gets is that the field of meta-epidemiology has seen a 
geometric growth during the last decade, with each year seeing more meta-epidemiological 
studies being published. This can also be seen from this overview, where the 59% (33 of 56) of 
all identified meta-epidemiological studies were published in the last five years.  
Secondly, considerable heterogeneity exists in the methods used in the included meta-
epidemiological studies pertaining to (i) the collection of eligible systematic review articles and 
the data extracted from them, (ii) the dealing with important issues like clustering, existence of 
multiple trial arms or reclassification of outcomes, (iii) heterogeneity among eligible 
trials/reviews, and (iv) any measures undertaken to control confounding. The methodological 
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aspect becomes even more complex, when we consider that different outcomes are used 
(binary, continuous, time-to-event or combinations of them) and that many of the above-
mentioned methods are applied on three distinct levels: within-trial, within-meta-analysis (across-
trials), and across-meta-analyses. Additionally, the same variability can be seen in the statistical 
analyses used within and across the included meta-analysis, as well as any additional analyses 
performed like subgroup analyses, meta-regressions, sensitivity analyses or assessments of 
reporting biases. 
One helpful step in order to safely navigate this maelstrom of discordant research 
methods / results would be to move in the direction of guidance, if not standardization, of meta-
epidemiological methods. Most well-conducted meta-epidemiological overviews have loosely 
adopted a framework of systematic review methodology. Therefore, a guiding source for the 
conduct and reporting of such studies, sort of a Cochrane Handbook and PRISMA statement, 
respectively, but for meta-epidemiological studies would surely aid towards consistent methods 
and complete reporting. Additionally, comparative assessments of the various alternatives for 
each meta-analytical step (both within- and across meta-analyses) would help identify which 
methods are more robust and should be preferred over the rest. At the present stage, such 
comparative endeavors are sparse and mostly based on simulation studies, rather than real 
empirical databases. This would further aid in the standardization of the methodological part of 
meta-research. 
Finally, although meta-epidemiological studies are very informative from an 
epistemological point of view, clinical translation of such empirical research remains its main 
scope. In this sense, meta-epidemiological evidence can be used in order to guide the eligibility 
criteria and literature searches of systematic reviews. Furthermore meta-epidemiological 
evidence can be directly incorporated into tools that assess the internal validity or risk of bias of 
trials included in a systematic review. Last, but not least, the GRADE approach [3] has proved to 
be a powerful tool in the armamentarium of systematic review authors, by clinically translating 
their results, and therefore has gained widespread acceptance. Using the GRADE approach in a 
meta-epidemiological study can be challenging, if not impossible. For example, Giraudeau et al. 
[4] recently introduced a sample size calculation for meta-epidemiological studies, which could 
be used to judge, if an adequate number of systematic reviews have been included in an 
overview, and therefore partially its imprecision. However, assessing the other domains of the 
GRADE approach is not that straightforward and a formal re-working of the GRADE approach 
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would enable consistent judgments about our confidence in existing meta-epidemiological 
findings, and ultimately enhance the scientific method. 
The authors of the present study are to be congratulated for their fine contribution in the 
field of meta-epidemiology and it is hoped that this will be built upon by the rest of the scientific 
community. 
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